Replies to post #138625 on Biotech Values

[mcbio]

1- What % of women at FR++?

I want to know this as well. Presumably it's a small percentage but I also don't think we need a huge market given current market cap and assuming ECYT ultimately does get approval (obviously, an unknown).

2- Curious what imbalances would have specifically caused such different results.

I think this refers to what they cited in the PR pertaining to the initial results wherein the control arm patients received platinum-based therapy at nearly twice the rate of the EC145 arm (#msg-73089346 ).

[rkrw]

40% are FR++ according to ECYT.

http://tinyurl.com/7krhdn7

Also of note they own the diagnostic, so that should add to revenues, if approved, since all would be tested.

[turtlepower]

ECYT - Not sure that the company had publicly stated the percentage of FR++. The percentage who are at least FR+ is 80% of Ovarian cancer patients.

I think they adjusted for platinum use, perhaps age and geography and also time since last platinum use. One of their theories for the OS being longer in the control arm was that more patients had been placed on platinum post trial and more of those patients had been platinum free for greater than 3 months which made them more platinum sensitive.